


LIVE WEBINAR

Hypertension and beyond






Thursday, 11 November 2021

from 11:00 to 12:00 CET

from 14:00 to 15:00 GST

from 18:00 to 19:00 CST





OVERVIEW

This live educational webinar will examine advances in the role of the sympathetic nervous system in the pathogenesis of cardiovascular disease. Recent European Society of Hypertension (ESH)/European Society of Cardiology (ESC) Hypertension Guidelines introduced increased heart rate (an indirect marker of increased sympathetic activity) as a negative prognostic factor in patients with hypertension. With this in mind, it is important to address the mechanisms, (including novel ones) involved in increasing sympathetic tone.

While sleep apnea syndrome is widely recognized as an important mechanism, it can be neglected in the diagnostic work-up of patients with hypertension, and often little attention is given to psycho-social risk, an emerging and strong cardiovascular risk factor.

Another vital and topical issue in cardiovascular medicine is the treatment of patients with heart failure, particularly the emergence of evidence demonstrating the beneficial effects of new drug classes. Recently, a SGLT-2 inhibitor has been shown to be effective in patients with heart failure, including those with HFpEF.

Beta-blockers remain the corner stone of treatment of patients with heart failure, but these new developments should fundamentally and positively change daily clinical practice and treatment of patients. This webinar will provide useful and informative scientific evidence supporting these important changes.

LEARNING OBJECTIVES

By attending this live educational webinar learners will be able to:

- Discuss the mechanisms through which an increase in sympathetic nervous system activity can lead to cardiovascular events
- Describe recent evidence demonstrating how obstructive sleep apnea syndrome and psycho-social stress can increase sympathetic nervous system activity
- Discuss the best therapeutic strategy to treat patients with heart failure according to International Guidelines
- Illustrate how, despite the availability of new drugs, beta-blockers remain the corner stone of the treatment of heart failure.

TARGET AUDIENCE

This activity is designed for Cardiologists, General Practitioners, Internists and those treating patients with cardiovascular disorders.

LANGUAGE

The official language of this live educational activity is English.

Simultaneous translation into Arabic and Mandarin Chinese will be provided.

REGISTRATION

To access the live webinar, please register by clicking on the below link:

<https://www.elearning.scientificseminars.com/the-2021-digital-learning-journey-on-hypertension/live-webinar/>

and complete a very short survey covering your current knowledge of the subject matter prior to attending the webinar.

CONTINUING MEDICAL EDUCATION

The Hypertension and beyond, Rome, Italy, 11/11/2021-11/11/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **1 European CME credit (ECMEC®)**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.




CME PROVIDER

Scientific Seminars International Foundation

Senior CME Manager: Flaminia Masprone

T +39 380 1504116 - F +39 06 4827169

info@scientificseminars.com



FACULTY

Rosa Maria Bruno


Paris Cardiovascular Research Centre - PARCC
Université de Paris
Paris, France

Erland Erdmann

Emeritus Director of the Clinic for Cardiology
Heart Centre of the University of Cologne
Cologne, Germany

Stefano Taddei

Director of the Hypertension Unit
Department of Clinical and Experimental Medicine
University of Pisa, Italy



AGENDA


THURSDAY, 11 NOVEMBER 2021

from 11:00 to 12:00 CET

11.00		Welcome and introduction S. Taddei (Italy)
11.05	L1	Increased sympathetic nervous system activity and cardiovascular risk: role of new conspirators R. M. Bruno (France)
11.25	L2	Heart failure: how to tailor treatment combining old and new drugs E. Erdmann (Germany)
11.45	P	Panel discussion
11.55		Closing remarks S. Taddei (Italy)
12.00		End of the live webinar

LEGEND

L: Lecture; **P:** Panel discussion



FACULTY DISCLOSURES

Scientific Seminars International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labelling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement nor a recommendation on the part of Scientific Seminars International Foundation. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Rosa Maria Bruno

Declared no potential conflict of interest.

Erland Erdmann

Declared receipt of honoraria or consultation fees from Merck, Bayer, Novartis and Res Med and participation in Merck; Bayer and Res Med speaker's bureau.

Stefano Taddei


Declared receipt of grants and contracts from Boehringer Ingelheim, Servier, Idorsia, Medtronic and Regione Toscana and participation in Servier, Merck, Sandoz and Neopharmed speaker's bureau.

CHAIRMAN



Stefano Taddei (Italy)

Professor Stefano Taddei is a Professor of Internal Medicine, working currently as the Director of the Department of Clinical and Experimental Medicine and Head of the Hypertension Unit of the University Hospital, Pisa, Italy. Professor Taddei is a Fellow of the European Society of Cardiology, the European, International and American Society of Hypertension, the European Society of Clinical Investigation, the High Blood Pressure Council of the American Heart Association, and the Italian Society of Hypertension. He served as a councillor for the Italian Society of Hypertension from 2007 until 2009. He is a member of the editorial boards of Hypertension, Blood Pressure, Journal of Cardiovascular Pharmacology, Current Vascular Pharmacology, Current Hypertension Reviews, High Blood Pressure and Cardiovascular Prevention and Journal of American Society of Hypertension. He is a deputy editor of the European Heart Journal. Professor Taddei's main research area is local neuro-humoral control of peripheral vessels in primary and secondary forms of hypertension, with particular emphasis on the sympathetic nervous system, the renin-angiotensin system and the endothelium. He is also interested in the assessment of target-organ damage in hypertension, including vascular and cardiac structural alterations and the clinical pharmacology of cardiovascular drugs. Professor Taddei has participated in numerous clinical studies and is the authors of more than 370 original papers, reviews and editorials in international scientific journals (H index: 72; Impact Factor: >2300).



L1

Increased sympathetic nervous system activity and cardiovascular risk: role of new conspirators

Rosa Maria Bruno (France)

LEARNING OBJECTIVES:

- Discuss the mechanisms through which an increase in sympathetic nervous system activity can lead to cardiovascular events
- Describe recent evidence demonstrating how obstructive sleep apnea syndrome and psychosocial stress can increase sympathetic nervous system activity



Rosa Maria Bruno

Rosa Maria Bruno (MD, PhD) is a specialist in hypertension, working currently as a researcher at the Paris Cardiovascular Research Center (PARCC-INSERM) and as a lecturer in Clinical Pharmacology at the University of Paris, France. Her clinical activity is focused on management of resistant hypertension, renovascular hypertension and hypertension in pregnancy. Her main field of research is the non-invasive evaluation of functional and structural vascular alterations due to traditional and emerging cardiovascular risk factors, as well as sympathetic regulation of vascular function in hypertension. She has authored >130 publications in peer-reviewed, PubMed-indexed scientific journals, with a H-index of 29 and >2700 citations. Dr Bruno is a member of the ESC Council of Hypertension Nucleus and of the Executive Committee of the Artery Society as well as Vice-leader of the Working Group 'Large Arteries' for the European Society of Hypertension. She is among the initiators of the European Collaboration in Science and Technology (COST) Action VascAgeNet and she leads the COVID-19 effects on ARTERial Stiffness and vascular AgiNg (CARTESIAN) study.

L2

Heart failure: how to tailor treatment combining old and new drugs

Erland Erdmann (Germany)


LEARNING OBJECTIVES:

- Discover the mechanisms that lead to the development of heart failure in hypertensive patients
- Learn the pathophysiologic basis for heart failure treatment.
- Understand why reduction of high heart rate is needed and helpful in heart failure
- Identify the need to tailor treatment in HFrEF
- Find out how newly available drugs are beneficial



Erland Erdmann

Erland Erdmann trained in cardiology at the University of Göttingen and the University of Munich, Germany, where he headed the cardiac catheterization laboratory from 1982 until 1993. From 1993 until 2012 he was Director of the Department of Internal Medicine at the University of Cologne, and head of the clinic for cardiology, angiology, pneumology and intensive care medicine at the university. In 2003, he was elected president of the German Cardiac Society (DGK). Professor Erdmann is editor and co-editor of several scientific journals and editor of the leading German textbook for cardiology (now 8th edition) 'Klinische Kardiologie', Springer-Nature. Since 2012, he has served as Professor Emeritus, lecturing and writing. His main scientific interests are the pathophysiology and treatment options of heart failure as well as the role of hypertension and diabetes in cardiovascular diseases. He has served on the steering committees of several major drug and device trials working to improve cardiovascular diseases, including CIBIS I – III, CARE-HF, PROACTIVE, SERVE-HF, NECTAR-HF and MOOD-HF.



All Scientific Seminars International Foundation programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of Scientific Seminars International Foundation. This independent educational program is made possible thanks to an educational grant received from Merck Healthcare KGaA Darmstadt Germany.



Scientific Seminars International Foundation
Via di Porta Pinciana, 6 - 00187 Roma
www.scientificseminars.com